We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 25

Federal Court deviates from established tests for patent listing Gilead Sciences, Inc. v. Canada (Health)
  • Gowling WLG
  • Canada
  • March 22 2016

In the decision summarized below, Apotex successfully obtained a dismissal of Gilead's application for a prohibition order in respect of Canadian


Changes at PMPRB to safeguard against excessively priced medicines
  • Gowling WLG
  • Canada
  • February 9 2016

Over the course of the next three years, PMPRB is seeking to change to its operations with the aim of becoming a more effective and stronger consumer


Health Canada seeks comment on revised SEB Guidance Document: New requirements for SEB sponsors
  • Gowling WLG
  • Canada
  • January 20 2016

On Dec. 7, 2015, Health Canada released a revised Guidance Document for sponsors of Subsequent Entry Biologics (SEB). The proposed revisions


PM(NOC) regulation amendments now in force
  • Gowling WLG
  • Canada
  • June 30 2015

Industry Canada has now enacted the amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations) in order to permit claims


Industry Canada seeks comment on proposed changes to listing requirements under the PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • May 6 2015

On May 2, 2015, the Governor in Council issued proposed amendments to Sections 2, 3, and 4 of the Patented Medicines (Notice of Compliance


Federal Court rejects NIA defence and awards compound interest on patent damages
  • Gowling WLG
  • Canada
  • January 24 2015

On Jan. 23, 2015, the Federal Court released its decision regarding the quantum of damages recoverable by Eli Lilly (“Lilly”) in an action relating


Supreme Court upholds Ontario restrictions on Formulary listing of private label products
  • Gowling WLG
  • Canada
  • November 22 2013

In a 7-0 decision released November 22, 2013, the Supreme Court found that the DIDFA & ODBA regulations are valid and that companies controlled by


Federal court rejects PMPRB Copaxone decision on excessive prices again
  • Gowling WLG
  • Canada
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second


Utility, sound prediction and promise of the patent
  • Gowling WLG
  • Canada
  • April 22 2013

In recent years, attacks on the lack of sound prediction and failure to meet the promise of the patent have proven to be a crushing hammer in the


Court affirms utility of Gleevec patent
  • Gowling WLG
  • Canada
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J